Karl Skriner

This inventor holds 6 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Charité – Universitätsmedizin Berlin. Active years: 2013-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karl Skriner. Retrieved from https://idiyas.com/inventor/karl-skriner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 6)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 2.3

ph-index = 1

Company Filing History:

4 out of 1,334

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

3 out of 283

Charité – Universitätsmedizin Berlin

patents

where one patent can have more than one assignee

Years Active: 2013-2018

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10041947 - Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment (2018-08-07),

2. 9880168 - Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment (2018-01-30),

3. 9335329 - Diagnostic prediction of rheumatoid arthritis and systemic lupus erythematosus (2016-05-10),

4. 9221881 - Markers for the diagnosis of celiac disease (2015-12-29),

5. 9052312 - Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment (2015-06-09),

6. 8597955 - HNRNP A3 related peptides and use thereof for diagnosis of rheumatoid arthritis (2013-12-03),

Title: The Innovations of Karl Skriner

Introduction

Karl Skriner is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of medical diagnostics, particularly in the area of anti-tumor treatments. With a total of six patents to his name, Skriner's work has the potential to impact patient care and treatment outcomes.

Latest Patents

One of his latest patents focuses on a biomarker for predicting responsiveness to anti-tumor necrosis factor alpha (TNF) treatment. This invention outlines a method for diagnosing individuals who are undergoing or are to undergo anti-TNF treatment. The method involves detecting immunoglobulins against specific biomarker proteins in bodily fluids or excrement. Based on this detection, individuals can be classified as either responders or non-responders to the treatment. Additionally, the patent includes diagnostic kits that utilize these biomarker proteins to assess treatment responsiveness.

Career Highlights

Throughout his career, Karl Skriner has worked with prestigious organizations such as the Max Planck Society for the Advancement of Science and Charité – Universitätsmedizin Berlin. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Zoltán Konthur and Hans Lehrach. Their collaborative efforts have further advanced the research and development of innovative diagnostic methods.

Conclusion

Karl Skriner's contributions to medical diagnostics through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for improved treatment strategies for patients undergoing anti-TNF therapies.

Profile summary based on public USPTO records.